CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment
CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to announce a collaboration with the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs). Together, the companies aim to make cancer treatments more affordable and accessible to all Americans. Through the relationship announced today, patients with a CureMatch report can now use Cost Plus Drugs to get lower prices on cancer medications in any combination treatment their doctor prescribes. This collaboration aligns with the goals of more access to innovative oncology treatments, laid out in President Biden’s Cancer Moonshot initiative, of which CureMatch is a partner.